RT Journal Article
SR Electronic
T1 <sup>177</sup>Lu-PSMA Therapy
JF Journal of Nuclear Medicine Technology
JO J. Nucl. Med. Technol.
FD Society of Nuclear Medicine
SP 205
OP 212
DO 10.2967/jnmt.122.263814
VO 50
IS 3
A1 Ephraim E. Parent
A1 Bital Savir-Baruch
A1 Isis W. Gayed
A1 Frankis Almaguel
A1 Bennett B. Chin
A1 Austin R. Pantel
A1 Evan Armstrong
A1 Amanda Morley
A1 Robin C. Ippisch
A1 Robert R. Flavell
YR 2022
UL http://tech.snmjournals.org/content/50/3/205.abstract
AB Radiopharmaceutical therapy using 177Lu-prostate-specific membrane antigen (PSMA) is an effective prostate cancer treatment that was recently approved by the U.S. Food and Drug Administration. This method leverages the success of PSMA-targeted PET imaging, enabling delivery of targeted radiopharmaceutical therapy; has demonstrated a clear benefit in large prospective clinical trials; and promises to become part of the standard armamentarium of treatment for patients with prostate cancer. This review highlights the evidence supporting the use of this agent, along with important areas under investigation. Practical information on technology aspects, dose administration, nursing, and the role of the treating physician is highlighted. Overall, 177Lu-PSMA treatment requires close collaboration among referring physicians, nuclear medicine technologists, radiopharmacists, and nurses to streamline patient care.